Clinical Trials
70 trialsSACHI
Hutchmed
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
BOLSTER
Lisata Therapeutics, Inc.
eVOLVE-02
AstraZeneca
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
MK-3475-01E
Merck Sharp & Dohme LLC
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
KANDLELIT-007
Merck Sharp & Dohme LLC
NeoCOAST-2
AstraZeneca
TroFuse-019
Merck Sharp & Dohme LLC
PanTumor-101
GlaxoSmithKline
TROPION-Lung12
AstraZeneca
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
TroFuse-036
Merck Sharp & Dohme LLC
RELATIVITY1093
Bristol-Myers Squibb
TeLuRide-008
Eikon Therapeutics
HERIZON-GEA-01
Jazz Pharmaceuticals
SUNRAY-01
Eli Lilly and Company
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
KRAScendo 170
Hoffmann-La Roche
SOHO-02
Bayer
MountainTAP-29
Bristol-Myers Squibb
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
MK-7339-012
Merck Sharp & Dohme LLC
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
Daiichi Sankyo
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
INTerpath-009
Merck Sharp & Dohme LLC
TROPION-Lung15
AstraZeneca
DESTINY-BTC01
AstraZeneca
CheckMate-1533
Bristol-Myers Squibb
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
KEYNOTE 975
Merck Sharp & Dohme LLC
DG-03
AstraZeneca
KUNLUN
AstraZeneca
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
MYSTIC
AstraZeneca
MK-3475-689
Merck Sharp & Dohme LLC
MAGELLAN
AstraZeneca
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.